Clinical trials: Migraine Headache
Pain, Migraine
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
- Trial name
- NCT01248468
- Testing
- Aspirin, acetaminophen and caffeine, Sumatriptan
- Where
- 20 sites in United States
- Volunteers
- 752 people
- Sponsor
- Novartis
Migraine
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for…
- Trial name
- NCT05375097
- Testing
- Erenumab
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
- Trial name
- NCT04218162
- Testing
- Lasmiditan 50mg, Lasmiditan 100mg
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Migraine
Real-world Data Analysis of REN Treatment in Migraine Patients
Data analysis concerning four sets of metrics: A. Per-treatment patterns of REN use as a standalone treatment vs. in combination with medications. B.
- Trial name
- NCT04992897
- Testing
- Remote Electrical Neuromodulation (REN)
- Where
- 2 sites in United States, Israel
- Volunteers
- 12,151 people
- Sponsor
- Theranica
Episodic Migraine
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
- Trial name
- NCT03700320
- Testing
- Standard of Care (SOC) Migraine Preventive Medication, Atogepant
- Where
- 112 sites in United States
- Volunteers
- 744 people
- Sponsor
- Allergan
Migraine
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
This two-stage clinical trial will assess a novel combination therapy for acute migraine. In Stage 1 (factorial), participants will receive the combination, each individual component, or placebo.
- Trial name
- AT-06 (NCT05685225)
- Testing
- Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen
- Where
- United States
- Sponsor
- Allodynic Therapeutics, Inc
Migraine Without Aura
Migraine STImulation Crisis of Migraine
Migraine is a neurovascular disease whose prevalence is estimated at almost 20% of the adult population. Currently, there is no treatment for migraine.
- Trial name
- MISTIC (NCT04568252)
- Testing
- Wristband with millimeter wave emission.
- Where
- 6 sites in France
- Volunteers
- 140 people
- Sponsor
- Remedee SA
Chronic Migraine
Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine
An non controlled, long term, multi center investigation
- Trial name
- NCT05843721
- Testing
- KOS (Intranasal kinetic oscillation stimulation)
- Where
- 12 sites in Germany, Israel and 2 more
- Volunteers
- 98 people
- Sponsor
- Chordate Medical
Migraine
Real World Effectiveness of Eptinezumab in Participants With Migraine
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM).
- Trial name
- EVEC (NCT05284019)
- Testing
- Eptinezumab, Erenumab, Onabotulinumtoxin-A
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lundbeck A/S
Migraine Disorders
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
- Trial name
- NCT01516892
- Testing
- onabotulinumtoxinA
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 716 people
- Sponsor
- Allergan
Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
- Trial name
- NCT01617941
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Migraine, Common Migraine
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg per day) compared with placebo in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00231595
- Testing
- topiramate
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine With Aura, Migraine Without Aura
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT03874832
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Acute Migraine
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
- Trial name
- Zotrip (NCT02745392)
- Testing
- ZP-Zolmitriptan
- Where
- 36 sites in United States
- Volunteers
- 365 people
- Sponsor
- Zosano Pharma Corporation
Migraine Headache, Cognitive Impairment
Treximet in Acute Migraine Headache: Assessing Cognitive Function
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting.
- Trial name
- NCT00837044
- Testing
- Treximet, Migraine rescue medication of choice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurological Research Center
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Vertigo
Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting
This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices.
- Trial name
- NCT04869020
- Testing
- Otoband
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Otolith Labs
Migraine
Open-trial on the Prevention of Chronic Migraines With the CEFALY Device
The main objective of this study was to assess the safety and efficacy of the Cefaly® e-TNS device as a prophylactic treatment of chronic migraine in adult patients.
- Trial name
- NCT02342743
- Testing
- CEFALY
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Cefaly Technology
Migraine
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
- Trial name
- CONQUER (NCT03559257)
- Testing
- Galcanezumab
- Where
- 69 sites in United States, Belgium and 11 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Migraine
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
- Trial name
- NCT00384774
- Testing
- Lasmiditan
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company